Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs BP 14979 (Primary)
- Indications Restless legs syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Bioprojet
- 09 Jul 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 09 Jul 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
- 07 Feb 2018 Status changed from not yet recruiting to recruiting.